Scarica l'app Stockscreener
1.8077
2.15%
-0.0523
Precedente Chiudi:
$1.86
Aprire:
$1.85
Volume 24 ore:
11,319
Relative Volume:
0.02
Capitalizzazione di mercato:
$2.74M
Reddito:
$502.40K
Utile/perdita netta:
$-7.91M
Rapporto P/E:
-0.1813
EPS:
-9.972
Flusso di cassa netto:
$-4.32M
1 W Prestazione:
+14.47%
1M Prestazione:
-41.86%
6M Prestazione:
-73.63%
1 anno Prestazione:
-88.52%
Intervallo 1D:
$1.8058
$1.885
Intervallo di 1 settimana:
$1.41
$1.89
Portata 52W:
$1.41
$35.99
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Nome
60 Degrees Pharmaceuticals Inc
Settore
Industria
Telefono
202-327-5422
Indirizzo
1025 CONNECTICUT AVENUE NW, WASHINGTON
Confronta SXTP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
1.8058 | 2.74M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.80 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.17 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.04 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.41 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.35 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
60 Degrees Pharmaceuticals Inc Borsa (SXTP) Ultime notizie
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given Sell (E+) Rating at Weiss Ratings - Defense World
Research Analysts Issue Forecasts for SXTP Q4 Earnings - Defense World
HC Wainwright Reaffirms “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
What is HC Wainwright’s Estimate for SXTP Q1 Earnings? - Defense World
60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split; shares fall - MSN
A company insider recently bought 6,000 shares of 60 Degrees Pharmaceuticals Inc [SXTP]. Should You Buy? - Knox Daily
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - GlobeNewswire
From Malaria to New Markets: How This Pharma CEO Plans to Transform ARAKODA's Future - StockTitan
60 Degrees Pharmaceuticals enacts reverse stock split By Investing.com - Investing.com Nigeria
60 Degrees Pharmaceuticals enacts reverse stock split - Investing.com India
60 Degrees Pharmaceuticals to Implement 1-for-5 Reverse Stock Split; Shares Down - Marketscreener.com
60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing Requirements - Nasdaq
Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan
Weiss Ratings Reaffirms “Sell (E+)” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
60 Degrees Pharmaceuticals files to sell 3.74M shares of common stock for holders - MSN
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® - The Manila Times
60 Degrees Gets FDA Clearance to Import Antimalarial From Australia to Ensure Supply Continuity - Marketscreener.com
Sixty Degrees Pharmaceuticals to Ensure Continuity of - GlobeNewswire
Malaria Drug Shortage Averted: FDA Green-Lights Australian Import for Critical U.S. Supply - StockTitan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
Bioceres Crop Solutions Corp (BIOX) Becoming More Attractive for Investors - Knox Daily
Balance Sheet Insights: 60 Degrees Pharmaceuticals Inc (SXTP)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Insiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55 - Simply Wall St
60 Degrees Pharmaceuticals Inc [SXTP] Records 200-Day SMA of $1.8142 - Knox Daily
60 Degrees Pharmaceuticals, Inc. Closes Registered Direct Offering and Concurrent Private Placement Raising Approximately $1.075 Million - Nasdaq
Pharmaceutical Funding Alert: 60 Degrees Secures Fresh Capital Through Strategic Share Offering - StockTitan
Form 424B5 60 DEGREES PHARMACEUTICA - StreetInsider.com
How does 60 Degrees Pharmaceuticals Inc (SXTP) change from a tortoise to a hare? - SETE News
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering - citybiz
60 Degrees Pharmaceuticals Secures $1.1 Mln In Registered Direct Offering - Nasdaq
60 Degrees Pharmaceuticals, Inc. Announces $1.075 Million Registered Direct Offering and Concurrent Private Placement of Common Stock and Warrants - Nasdaq
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Pharma Stock Alert: SXTP Secures Fresh Capital Through Strategic Share Offering at $0.715 - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
SXTP stock touches 52-week low at $0.7 amid market challenges - MSN
60 Degrees Pharmaceuticals, Inc. Closes Registered Direct Offering and Concurrent Private Placement Raising Approximately $1.043 Million - Nasdaq
60 Degrees Pharma Announces Closing of $1.043 Million - GlobeNewswire
60 Degrees Pharma Secures Fresh Capital: Inside the $1M Financing Deal That's Turning Heads - StockTitan
60 Degrees Pharmaceuticals announces stock and warrant sale - MSN
US Stocks Mixed; General Dynamics Earnings Top Views - Benzinga
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Pharma Company's $1M Cash Injection Comes with Hidden UpsideComplete Analysis - StockTitan
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial - Yahoo! Voices
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
60 Degrees Pharmaceuticals Gets Investigational Review Board Approval for Babesiosis Phase 2 Study - Marketscreener.com
60 Degrees Pharmaceuticals, Inc. Announces the Approval of an Investigational Review Board Commissioned Phase II Clinical Study - Marketscreener.com
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewswire
60 Degrees Pharmaceuticals Inc Azioni (SXTP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
60 Degrees Pharmaceuticals Inc Azioni (SXTP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
| XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
| DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
| DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
| DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
| DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
| DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
| DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
| XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
| XU CHERYL | Director |
May 16 '24 |
Option Exercise |
0.22 |
2,000 |
446 |
228,934 |
5.68%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):